Table 7.
Short-term curative effects of patients with EGFR L858R mutation
| Curative effects | I+C (group A2, n=28) | I (group B2, n=33) | C (group C2, n=28) |
|---|---|---|---|
| Best response | |||
| CR | 0% (n=0) | 0% (n=0) | 0% (n=0) |
| PR | 53.6% (n=15) | 42.4% (n=14) | 28.6% (n=8) |
| SD | 39.3% (n=11) | 48.5% (n=16) | 42.8% (n=12) |
| PD | 7.1% (n=2) | 9.1% (n=3) | 28.6% (n=8) |
| ORR (%) | 53.6 | 42.4 | 28.6 |
| DCR (%) | 92.9 | 90.9 | 71.4 |
Abbreviations: C, chemotherapy; CR, complete remission; DCR, disease control rate; EGFR, epidermal growth factor receptor; I, icotinib; I+C, icotinib+chemotherapy; ORR, overall response rate; PD, progression disease; PR, partial disease; SD, stable disease.